WO2023018243A1 - Système non invasif de dosage de glycémie - Google Patents

Système non invasif de dosage de glycémie Download PDF

Info

Publication number
WO2023018243A1
WO2023018243A1 PCT/KR2022/011983 KR2022011983W WO2023018243A1 WO 2023018243 A1 WO2023018243 A1 WO 2023018243A1 KR 2022011983 W KR2022011983 W KR 2022011983W WO 2023018243 A1 WO2023018243 A1 WO 2023018243A1
Authority
WO
WIPO (PCT)
Prior art keywords
blood glucose
measuring
spectroscopic
age
unit
Prior art date
Application number
PCT/KR2022/011983
Other languages
English (en)
Korean (ko)
Inventor
이병수
Original Assignee
주식회사 템퍼스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 템퍼스 filed Critical 주식회사 템퍼스
Publication of WO2023018243A1 publication Critical patent/WO2023018243A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/053—Measuring electrical impedance or conductance of a portion of the body
    • A61B5/0535—Impedance plethysmography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/053—Measuring electrical impedance or conductance of a portion of the body
    • A61B5/0537—Measuring body composition by impedance, e.g. tissue hydration or fat content
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1495—Calibrating or testing of in-vivo probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B2560/00—Constructional details of operational features of apparatus; Accessories for medical measuring apparatus
    • A61B2560/02—Operational features
    • A61B2560/0242—Operational features adapted to measure environmental factors, e.g. temperature, pollution
    • A61B2560/0247—Operational features adapted to measure environmental factors, e.g. temperature, pollution for compensation or correction of the measured physiological value

Definitions

  • the present invention relates to a blood glucose measurement system, and more particularly to a non-invasive blood glucose measurement system.
  • the invasive blood glucose meter In the invasive blood glucose measurement, blood is collected from a user through a needle or an injection to measure a blood glucose level. Therefore, the invasive blood glucose meter causes physical pain to the user due to blood collection. In addition, if the invasive blood glucose meter is not maintained cleanly, a user may be infected with bacteria, and it is difficult to measure the blood glucose level effectively because it is difficult to measure it constantly.
  • the non-invasive blood glucose measurement is a blood glucose measurement that does not involve body blood, does not cause physical pain, and can be measured at all times, so that blood sugar can be effectively managed.
  • Various methods have been proposed and studied as non-invasive blood glucose measurement methods, but the methods proposed to be reliable include blood glucose measurement using infrared spectroscopy using FTIR (Fourier transform InfraRed) spectrum or Raman spectrum, blood glucose meter using electromagnetic field, There is a blood glucose meter using exhaled breath and a blood glucose meter using a patch.
  • FTIR Fastier transform InfraRed
  • the blood glucose meter using infrared rays irradiates the skin with infrared rays of various wavelengths, and analyzes the reflected light of the skin for the infrared rays with a sensor to measure the blood glucose level.
  • the aspects of the reflected light are all different according to various situations such as skin conditions, physical characteristics, and distribution of blood vessels, the amount of light measured by the sensor varies widely depending on the individual or the measurement time, making it difficult to apply in practice.
  • AGEs advanced glycation end-products
  • the concentration of AGE is proportional to the average blood glucose level for a long period of time
  • the concentration of AGE is used as an indicator of the average blood glucose level for a long period of time (about 15 days or less). Accordingly, since an error occurs in spectroscopic blood glucose measurement when the concentration of AGE changes, periodic calibration of the spectroscopic blood glucose measurement device is required.
  • An object of the present invention is to provide a blood glucose measurement system and a method for measuring blood sugar capable of compensating for individual differences or deviations due to measurement time and distinguishing blood sugar attached to final glycation end products.
  • these tasks are illustrative, and the scope of the present invention is not limited thereby.
  • a non-invasive blood glucose measurement system includes a spectroscopic blood glucose measurement unit for measuring a spectroscopic glucose content from an absorption spectrum for infrared rays of a body part, and fluorescence of ultraviolet rays of the body part AGE blood glucose measurement unit for measuring the content of glucose attached to the final glycation end product (AGE) from the AGE blood glucose measurement unit, and from the values measured by the spectroscopic blood glucose measurement unit and the AGE blood glucose measurement unit as a source of energy within the cells of the human body measurement part and a control unit that obtains actual blood glucose to be used.
  • a spectroscopic blood glucose measurement unit for measuring a spectroscopic glucose content from an absorption spectrum for infrared rays of a body part, and fluorescence of ultraviolet rays of the body part AGE blood glucose measurement unit for measuring the content of glucose attached to the final glycation end product (AGE) from the AGE blood glucose measurement unit, and from the values measured by the spectroscopic blood glucose measurement unit and
  • the spectroscopic blood glucose measurement unit includes an infrared emitting unit for radiating infrared rays to the body measurement region and an infrared sensor array including an infrared sensor array for analyzing an absorption spectrum within the body measurement region. can do.
  • the AGE blood glucose measurement unit detects visible light including an ultraviolet ray emitting unit for irradiating ultraviolet rays to the body measurement part and a visible light sensor array for measuring fluorescence by ultraviolet light from the body measurement part wealth may be included.
  • control unit subtracts the glucose content attached to the advanced glycation end products (AGE) measured by the AGE blood glucose measurement unit from the spectroscopic glucose content measured by the spectroscopic blood glucose measurement unit to obtain the real blood glucose. can be obtained.
  • AGE advanced glycation end products
  • the system further includes at least one sensor for measuring the temperature or humidity of the human body part or measurement environment, and the control unit measures the spectroscopic blood glucose to reduce the effect of temperature or humidity. Values measured by the unit and the AGE blood glucose measurement unit may be corrected with values measured by the at least one sensor.
  • the non-invasive blood glucose measurement system further includes a moisture meter for measuring moisture by measuring bio-impedance of the body part, and the control unit determines the total blood volume of the body part measured from the value measured by the moisture meter. , and the real blood glucose concentration can be obtained from the ratio of the real blood glucose to the total blood volume.
  • the moisture meter may include at least two contact terminals attachable to the body measurement part.
  • a non-invasive blood glucose measurement method includes the steps of measuring a spectroscopic glucose content from an absorption spectrum of an infrared ray of a human body measurement site through a spectroscopic blood glucose measurement unit, and the anthropometric measurement through an AGE blood glucose measurement unit Measuring the content of glucose attached to advanced glycation end products (AGEs) from fluorescence of ultraviolet rays of the site, and determining the energy source in the cells of the human body measurement site from the spectroscopic glucose content and the glucose content attached to the end glycation end products It may include the step of obtaining the real blood sugar used as .
  • AGEs advanced glycation end products
  • the step of measuring the moisture by measuring the bio-impedance of the human body part through a moisture meter wherein the step of obtaining the actual blood glucose is the value measured by the moisture meter.
  • the total blood volume of the human body part can be estimated from, and the real blood glucose concentration can be obtained from the ratio of the real blood glucose to the total blood volume.
  • FIG. 1 is a schematic block diagram showing a non-invasive blood glucose measurement system according to an embodiment of the present invention.
  • FIG. 2 is a schematic cross-sectional view showing a spectroscopic blood glucose measurement unit in a non-invasive blood glucose measurement system according to embodiments of the present invention.
  • FIG. 3 is a schematic cross-sectional view showing an AGE blood glucose measurement unit in a non-invasive blood glucose measurement system according to embodiments of the present invention.
  • FIG. 4 is a schematic cross-sectional view showing a moisture meter in a non-invasive blood glucose measurement system according to embodiments of the present invention.
  • FIG. 5 is a schematic flowchart showing a non-invasive blood glucose measurement method according to an embodiment of the present invention.
  • FIG. 1 is a schematic block diagram showing a non-invasive blood glucose measurement system 100 according to an embodiment of the present invention.
  • the non-invasive blood glucose measurement system 100 may include a spectroscopic blood glucose measurement unit 110, an AGE blood glucose measurement unit 120, and a control unit 150.
  • the spectroscopic blood glucose measuring unit 110 may be provided to measure a spectroscopic glucose content from an infrared absorption spectrum of a human body measurement site, for example, human skin.
  • the spectroscopic blood glucose measurement unit 110 may irradiate infrared rays of a predetermined wavelength range to the human body measurement part, and measure the reflected infrared rays after the reaction in the human body.
  • the spectroscopic blood glucose measuring unit 110 or the controller 150 analyzes the spectrum of the reflected infrared rays to know the absorption spectrum absorbed by glucose in the human body, and from this, it is possible to calculate the total glucose content in the human body.
  • the AGE blood glucose measuring unit 120 may be provided to measure the content of glucose attached to advanced glycation end products (AGE) from fluorescence of ultraviolet rays of the human body part.
  • the AGE blood glucose measuring unit 120 may irradiate ultraviolet rays of a predetermined wavelength range to the human body measurement part, and measure fluorescence emitted from the human body by reacting with the ultraviolet rays within the human body.
  • the AGE blood glucose measurement unit 120 or the controller 150 may calculate the amount of glucose attached to the final glycation end products in the human body by analyzing the fluorescence.
  • the control unit 150 may obtain real blood sugar used as a calorie source within the cells of the body part to be measured from values measured by the spectroscopic blood glucose measurement unit 110 and the AGE blood glucose measurement unit 120 . For example, the control unit 150 subtracts the glucose content attached to advanced glycation end products (AGEs) measured by the AGE blood glucose measurement unit 120 from the spectroscopic glucose content measured by the spectroscopic blood glucose measurement unit 110 to obtain actual blood glucose. can be obtained.
  • AGEs advanced glycation end products
  • the non-invasive blood glucose measurement system 100 may further include a moisture meter 130 for measuring moisture by measuring bio-impedance of a body part.
  • the controller 150 may estimate the total blood volume of the body part measured from the value measured by the moisture meter 130, and obtain the real blood glucose concentration from the ratio of the real blood glucose to the total blood volume.
  • the non-invasive blood glucose measurement system 100 may further include at least one sensor 140 for measuring temperature and/or humidity in a body part or measurement environment.
  • the sensor 1400 may be disposed in one or both of the spectroscopic blood glucose measurement unit 110 and the AGE blood glucose measurement unit 120, or may be separately provided in the non-invasive blood glucose measurement system 100.
  • the sensor 140 may include an infrared sensor capable of measuring temperature in a non-contact manner.
  • the control unit 150 may correct the values measured by the spectroscopic blood glucose measurement unit 110 and the AGE blood glucose measurement unit 120 with values measured by the sensor 140 in order to reduce the effect of temperature or humidity.
  • the controller 150 may be coupled to the spectroscopic blood glucose measurement unit 110 or the AGE blood glucose measurement unit 120 .
  • FIG. 5 is a schematic flowchart showing a non-invasive blood glucose measurement method according to an embodiment of the present invention.
  • the non-invasive blood glucose measurement method using the non-invasive blood glucose measurement system 100 through the spectroscopic blood glucose measurement unit 110, spectroscopically analyzes the absorption spectrum for infrared rays of the body part to be measured.
  • It may include a step (S30) of obtaining real blood glucose used as a calorie source within the cells of the body measurement site from the optical glucose content and the glucose content attached to the final glycation product.
  • the non-invasive blood glucose measurement method further includes a step (S30) of measuring moisture by measuring bio-impedance of a body part to be measured using the moisture meter 130, and in this case, obtaining actual blood sugar.
  • step (S40) the total blood volume of the human body part measured from the value measured by the moisture meter 130 can be estimated, and the real blood glucose concentration can be obtained from the ratio of the real blood glucose to the total blood volume.
  • the above-described step of measuring the spectroscopic glucose content (S10), measuring the content of glucose attached to the final glycation end product (AGE) (S20), and measuring the moisture (S30) can be performed independently of each other Bar, may be changed in any order.
  • spectroscopic blood glucose measurement unit 110 the AGE blood glucose measurement unit 120, and the moisture meter 130 in the non-invasive blood glucose measurement system 100 will be described in more detail.
  • FIG. 2 is a schematic cross-sectional view showing the spectroscopic blood glucose measurement unit 110 in the non-invasive blood glucose measurement system 100 according to embodiments of the present invention.
  • the spectroscopic blood glucose measuring unit 110 includes an infrared emitting unit 114 that irradiates infrared rays to the body measurement part 50 and an infrared sensor array for analyzing absorption spectrum in the body measurement part 50. It may include an infrared detection unit 116 to.
  • the infrared emitting unit 114 and the infrared sensing unit 116 may be installed in the body 112 where the light guiding space A is formed.
  • the body 112 may come into contact with the body part 50 , for example, human skin, and a light guiding space A may be formed in the body 112 to come into contact with the body part 50 .
  • the infrared light emitting unit 114 is installed at one end of the light guiding space A, and can generate measurement light L1 to measure the glucose concentration in the blood flowing inside the human body measurement part 50. there is.
  • the infrared sensor 116 may be installed at the other end of the light guiding space A and receive the reaction light L2 transmitted from the human body measurement part 50 .
  • the body 112 is a kind of box-shaped box with an open bottom that contacts a location where blood sugar measurement is easy using infrared rays, such as the skin of a human body, such as hands, feet, torso, ears, forehead, armpits, and thighs.
  • infrared rays such as the skin of a human body, such as hands, feet, torso, ears, forehead, armpits, and thighs.
  • various block or frame structures made of synthetic resin or metal and having sufficient strength and durability to support the above-described infrared emitting unit 114 and infrared sensing unit 116 may be used.
  • the infrared emitting unit 114 may include an LWIR light emitter such as an infrared LED or an infrared lamp that emits long wave infrared (LWIR) light. More specifically, as the infrared light emitting unit 114, all kinds of infrared light emitting devices capable of emitting irradiation light in a long-wavelength infrared band having a wavelength of 2.5 ⁇ m to 14 ⁇ m may be applied.
  • LWIR light emitter such as an infrared LED or an infrared lamp that emits long wave infrared (LWIR) light.
  • LWIR long wave infrared
  • the infrared sensor 116 is a sensor that receives the reaction light L2 transmitted from the body measurement part 50, and compares the measurement light L1 generated from the infrared light emitter 114 with the reaction light ( At least one first sensor (not shown) capable of measuring the overall reduction rate of L2) and at least one second sensor (not shown) capable of measuring the partial absorbance absorbed by glucose among the reaction light L2 can include
  • the first sensor may be an LWIR measuring sensor for detecting LWIR
  • the second sensor may be a glucose absorption wavelength band measuring sensor for detecting the glucose absorption wavelength band in LWIR.
  • an infrared sensor capable of mainly measuring a wavelength of a glucose component including a wavelength of 9.2 to 9.8 micrometers, which is a major absorption wavelength band, may be applied.
  • the first sensor and the second sensor are either thermal sensors or infrared sensors, and may be provided as thermopile sensors capable of statically and dynamically measuring temperature without self-heating.
  • the spectroscopic blood glucose measurement unit 110 is directed to the light guiding space A of the body 112 so that the measurement light L1 generated from the infrared light emitting unit 114 is reflected at least once from the human body measurement part 50.
  • An installed reflective layer (R) may be further included.
  • the reaction light L2 reflected from the human body part 50 may be reflected at least once by the reflective layer R and then be guided to the infrared sensor 116 .
  • the reflective layer R may be formed on one lower side of the infrared emitting unit 114, the other lower side of the infrared sensing unit 116, and the ceiling surface of the light guiding space A.
  • the reflective layer R is not necessarily limited to that shown in FIG. 2 and may be formed in various forms on the inner wall surface of the light guiding space A.
  • a third LWIR filter (F3) installed in may be further provided.
  • the irradiation light L1 may penetrate the human body measurement part 50 while passing through the second LWIR filter F2 and the first LWIR filter F1, and some of them may be transmitted to the light guiding space A. It may be reflected multiple times by the reflective layer R and re-irradiated to the human body part 50 .
  • the reaction light L2 may be detected by the infrared sensor 116 through the first LWIR filter F1 and the third LWIR filter F3.
  • FIG 3 is a schematic cross-sectional view showing the AGE blood glucose measurement unit 120 in the non-invasive blood glucose measurement system 100 according to embodiments of the present invention.
  • the AGE blood glucose measurement unit 120 includes an ultraviolet light emitting unit 124 that irradiates ultraviolet rays to the human body part 50 and a visible light sensor for measuring fluorescence by ultraviolet light from the body part 50
  • a visible light detector 126 including an array may be included.
  • the ultraviolet light emitting unit 124 and the visible light sensing unit 126 may be installed in the body 122 where the light guiding space A is formed.
  • the body 122 may come into contact with the body part 50 , for example, human skin, and a light guiding space A may be formed in the body 122 to come into contact with the body part 50 .
  • the ultraviolet light emitting unit 124 is installed at one end of the light guiding space A, and includes ultraviolet rays of a predetermined wavelength range to measure the glucose content attached to the final glycation end product (AGE) in the human body measurement part 50 It is possible to generate the measurement light L1 that The visible light sensor 126 is installed at the other end of the light guiding space A, and may receive the reaction light L2 including fluorescence by ultraviolet rays from the body part 50 .
  • the ultraviolet light emitting unit 124 includes a UV LED device that generates ultraviolet light in a wavelength range of 300 nm to 400 nm, and the visible light detector 126 measures fluorescence generated from advanced glycation end products (AGE).
  • AGE advanced glycation end products
  • a plurality of visible light sensor arrays capable of receiving visible light in a wavelength range of 400 nm to 650 nm or a visible light spectrum analyzer may be included.
  • the AGE blood glucose measuring unit 120 is installed in the light guiding space A of the body 122 so that the measurement light L1 generated from the visible light emitting unit 124 is reflected at least once from the human body measurement part 50 A reflective layer (R) may be further included. Furthermore, the reaction light L2 emitted from the body measurement part 50 may be reflected at least once by the reflective layer R and then be guided to the visible light sensor 116 .
  • the reflective layer R may be formed on one lower side of the visible light emitting unit 124, the other lower side of the visible light detecting unit 126, and the ceiling surface of the light guiding space A.
  • the reflective layer R is not necessarily limited to that of FIG. 3 and may be formed in various shapes on the inner wall surface of the light guiding space A.
  • an ultraviolet light transmission filter F2 is installed in the light guiding space A under the ultraviolet light emitting unit 124, and a visible light transmission filter F3 is installed in the light guiding space A under the visible light sensor 126.
  • the irradiation light L1 may penetrate the human body part 50 while passing through the UV transmission filter F2, and some of them may be transmitted to the light guiding space A and reflected multiple times by the reflective layer R. It can be re-irradiated as the human body part 50.
  • the reaction light L2 may be detected by the visible light detector 126 through the visible light transmission filter F3.
  • AGE blood glucose measurement unit 120 fluorescence formed by reacting the ultraviolet rays irradiated into the human body part 50 with glucose attached to the end glycation end product (AGE) can be detected. By spectral analysis of this fluorescence, the content of glucose attached to advanced glycation end products (AGEs) can be calculated.
  • FIG. 4 is a schematic cross-sectional view showing a moisture meter 130 in the non-invasive blood glucose measurement system 100 according to embodiments of the present invention.
  • the moisture meter 130 may include at least two contact terminals 132 and 134 attachable to the human body part 50 .
  • the moisture meter 130 may apply and receive an electrical signal of a predetermined frequency through the contact terminals 132 and 134 in order to measure the bioimpedance of the body part 50 .
  • the moisture meter 130 or the control unit 150 calculates bioimpedance from signals provided from the contact terminals 132 and 134, and considers data such as height, weight, age, and gender of the subject to measure the body part (50). ), and the total amount of blood in the body part 50 can be estimated from this water content.
  • the final glycation product obtained using the AGE blood glucose measurement unit 120 from the total glucose content obtained using the spectroscopic blood glucose measurement unit 110 ( By excluding the glucose content attached to AGE), it is possible to obtain actual blood sugar used as a substantial calorie source within the cells of the human body. Accordingly, it is possible to solve the problem that the glucose content attached to the final glycation product changes for each individual or according to measurement conditions, thereby changing the measured blood glucose value.
  • the non-invasive blood glucose measurement system 100 and the blood glucose measurement method using the same it is possible to measure relatively uniform blood sugar regardless of individual differences or measurement conditions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

Un système non invasif de dosage de glycémie selon un aspect de la présente invention comprend : une partie de dosage spectroscopique de glycémie pour mesurer une teneur spectroscopique en glucose à partir d'un spectre d'absorption de rayonnement infrarouge dans une région de mesure du corps humain ; une partie de dosage de glycémie AGE pour mesurer une teneur en glucose fixé à des produits finaux de glycation avancée (AGE) à partir de la fluorescence pour un rayonnement ultraviolet dans la région de mesure du corps humain ; et un dispositif de commande pour une glycémie substantielle utilisée en tant que source de calories dans des cellules de la région de mesure du corps humain à partir des mesures obtenues dans la partie de dosage spectroscopique de glycémie et la partie de dosage de glycémie AGE.
PCT/KR2022/011983 2021-08-11 2022-08-11 Système non invasif de dosage de glycémie WO2023018243A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2021-0105870 2021-08-11
KR1020210105870A KR102540285B1 (ko) 2021-08-11 2021-08-11 비침습 혈당 측정 시스템

Publications (1)

Publication Number Publication Date
WO2023018243A1 true WO2023018243A1 (fr) 2023-02-16

Family

ID=85200880

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/011983 WO2023018243A1 (fr) 2021-08-11 2022-08-11 Système non invasif de dosage de glycémie

Country Status (2)

Country Link
KR (1) KR102540285B1 (fr)
WO (1) WO2023018243A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060195022A1 (en) * 1998-04-06 2006-08-31 Pierre Trepagnier Non-invasive tissue glucose level monitoring
KR20120114777A (ko) * 2011-04-08 2012-10-17 한국전기연구원 최종당화산물의 자가형광 측정 장치
KR20190057743A (ko) * 2017-11-20 2019-05-29 삼성전자주식회사 생체정보 추정 장치 및 방법
KR20200029023A (ko) * 2017-08-23 2020-03-17 가부시키가이샤 리코 측정 장치 및 측정 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102390874B1 (ko) 2014-10-29 2022-04-26 삼성전자주식회사 혈당 측정기 및 그에 따른 혈당 측정 방법
KR101981632B1 (ko) * 2017-10-31 2019-05-24 주식회사 템퍼스 혈당 측정 장치
KR102033711B1 (ko) * 2018-02-19 2019-11-08 주식회사 템퍼스 비침습식 혈당 측정 방법 및 비침습식 혈당 측정 장치
KR102348087B1 (ko) * 2019-08-22 2022-01-06 재단법인 대구경북첨단의료산업진흥재단 글루코스 반응 형광 특성을 이용한 혈당 계측 시스템
KR102549236B1 (ko) * 2019-11-25 2023-06-30 한국전자통신연구원 혈당량 측정 장치 및 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060195022A1 (en) * 1998-04-06 2006-08-31 Pierre Trepagnier Non-invasive tissue glucose level monitoring
KR20120114777A (ko) * 2011-04-08 2012-10-17 한국전기연구원 최종당화산물의 자가형광 측정 장치
KR20200029023A (ko) * 2017-08-23 2020-03-17 가부시키가이샤 리코 측정 장치 및 측정 방법
KR20190057743A (ko) * 2017-11-20 2019-05-29 삼성전자주식회사 생체정보 추정 장치 및 방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAGHAVA ALOK, SIDRA ISLAM, BRIJESH KUMAR MISHRA, RINKESH KUMAR GUPTA, SUMIT SUMIT: "Optical screening of glycation induced structural alterations in serum proteins of diabetes patients using spectroscopic techniques", INTERNATIONAL JOURNAL OF NEW TECHNOLOGY AND RESEARCH (IJNTR), vol. 2, no. 5, 31 May 2016 (2016-05-31), pages 44 - 48, XP093034679, ISSN: 2454-4116 *

Also Published As

Publication number Publication date
KR102540285B1 (ko) 2023-06-07
KR20230023953A (ko) 2023-02-20

Similar Documents

Publication Publication Date Title
US8873035B2 (en) Systems and methods for correcting optical reflectance measurements
US5360004A (en) Non-invasive determination of analyte concentration using non-continuous radiation
JP5175179B2 (ja) 改良された分光測光による血液酸素化モニタリング方法
WO2019160272A1 (fr) Procédé non invasif de mesure du taux de glycémie et dispositif de mesure non invasif du taux de glycémie
PT948284E (pt) Monitorização de analitos de tecidos por radiação infravermelha
Tenhunen et al. Non-invasive glucose measurement based on selective near infrared absorption; requirements on instrumentation and spectral range
WO2019172570A1 (fr) Procédé de surveillance de la glycémie et dispositif portable de surveillance de la glycémie l'utilisant
KR970700859A (ko) 혈액 성분의 농도를 측정하기 위한 비 침투성 비 분광 광도 적외선 측정 방법(non-invasive non-spectrophotometric infrared measurement of blood analyte concentrations)
CN103249362A (zh) 用于血液参数的光学测量的系统、方法和计算机程序产品
CN107334477A (zh) 一种双光谱无创血糖检测装置
KR20190048706A (ko) 혈당 측정 장치
WO2023018243A1 (fr) Système non invasif de dosage de glycémie
US8077312B2 (en) Calibration device for a spectrophotometric system
EP0623307A1 (fr) Détermination non-invasive de la concentration de constituants par radiation non-continue
RU2732384C1 (ru) Устройство и способ для измерения насыщения кислородом крови в ткани пациента
CN111803085A (zh) 一种基于颜色特性的无创血红蛋白浓度水平测量装置
WO2013100552A1 (fr) Analyseur de radicaux libres d'oxygène et procédé afférent l'utilisant
WO2022184623A1 (fr) Biocapteur à double mode
WO2021132799A1 (fr) Procédé et dispositif type paramétrage de point d'auto-référence de mesure de constituants du sang
US5908384A (en) Apparatus for non-invasive measurement within a human or animal body
WO2019189970A1 (fr) Appareil et procédé de mesure de débit sanguin à fonction de correction du bruit dû à la pression
WO2023075465A1 (fr) Système et procédé pour mesurer la concentration de glucose à l'aide d'une imagerie par granularité laser à modulation photothermique, et support d'enregistrement sur lequel est enregistré un programme lisible par ordinateur pour exécuter le procédé
Liu et al. Spatial sensitivity of nirs tissue oxygenation measurement using a simplified instrument
Saetchnikov et al. Mobile e-health sensor for non-invasive multi parameter diagnostics of blood biochemistry
WO2022184633A1 (fr) Biocapteur à double mode

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22856238

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22856238

Country of ref document: EP

Kind code of ref document: A1